Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLIODIS: Disulfiram and Copper in Newly Diagnosed Glioblastoma
NCT01777919Phase 2Not yet recruiting
- Sponsor
- Olympion Medical Center
- Start
- Jan 2027
- Primary completion
- Jan 2029
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of disulfiram, copper sulfate in glioblastoma (GBM), sponsored by Olympion Medical Center. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
disulfiramcopper sulfate
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT01777919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01777919.